

STRATEGY FOR Week Commencing 22 June –

New Financial terminology is always a product that arises in times of uncertainty. In the 2008 financial crisis CDO's [Collateral Debt Obligations] was a term used to describe the ability to magnetise money from duffed debt. Alas the likes of Lehman, Barings and co often confused fantasy with reality as these were the institutions holding the package of manure in the end with nobody to pass it onto.

And so we come to today where the new kid on the block is 'liquidity infusion.' Central banks everywhere are doing what they can to manage economic catastrophe **through liquidity infusion**. In essence it's QE [Quantitative Easing] but with refinements. The scale of deficit financing that we now see in all major economies as a result of the pandemic has seen an unprecedented levels of financial support. In the UK a scheme designed to provide financial life support to the economy continues to assist.

Furloughing yes another term that has been assigned in the lexicon of financial language has been seen to be savour. Yet all good things come to an end and the jury still out on the effects of post corona. The winding down of any support scheme has dangers. Whatever ones view, there's no doubting that economic stagnation will become the new norm as job losses mount in the near future. Economic experts are now raising the debate of what kind of recession is about to hit, L, U, V or will it be the big D. Expect Governments now to turn to marketing providing subliminal persuasion to get their populations to do their bit to help economic recovery.

The circus has now begun in earnest in the US where the presidential elections begin to enter the framework for political debate. The cost of the pandemic continues relentlessly as the devastating effects continue to climb. Alas political leaders continue to look to manipulate current events for points scoring rather than look on what really will make a difference.

The portfolio continued in the negative last week with a -1.27% decline. Omega diagnostics continues to lose momentum consolidating around the mid 50p. Their recent notification of raising additional funding may well restrict share price elevation. Disappointing performers SDI, PSTI, Catalyst pharma and Bristol Myers Squibb continually frustrate. Retrograde June has still to finish and the market irrational exuberance continues to lead with frothy optimism. This week I look to see if price targets can be achieved with plueistem Therapeutics in mind. This week's commentary is short and sweet. Until Next Time.

[STRATEGY FOR Week Commencing 15 June](#) [Week Commencing 8 June](#)